1. Generics Bulletin
  2. >>Products
  3. >>Generics

Teligent Surprised By Orphan Generic Setback

FDA Wants More Information On Complex Generic

 
• By Aidan Fry

US niche generics specialist Teligent has expressed surprise at a complete response letter issued by the FDA over an application for a generic of an orphan drug.

Oliver_Twist
Teligent has suffered a setback in its bid to bring a generic of an orphan drug to the US market • Source: Shutterstock

Teligent has been surprised by a complete response letter issued over an abbreviated new drug application for its first complex drug indicated for an orphan disease population. “In the letter, the US Food and Drug Administration requested further information and raw data to support the ANDA,” revealed the US niche generics specialist, which is working on the orphan generic with an undisclosed development partner.

“This latest response from the FDA is unexpected given the time and opportunity that the FDA had to request the information during the ANDA’s active review,” commented Teligent’s president and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Sandoz Leads Charge With First US Denosumab Launch

 
• By Dave Wallace

Competition to Amgen’s Prolia and Xgeva denosumab brands has hit the US market, with Sandoz taking the lead by launching its interchangeable Jubbonti and Wyost biosimilars.

‘Obsessive’ Teva Aims For $800m Biosimilar Sales By 2027

 
• By Dean Rudge

Teva says it is now in the “accelerate growth” phase of its strategic roadmap, with global biosimilar launches set to help the firm achieve its goals.

Trump-Trimmed FDA Finally Releases A Batch Of PSGs – Back To Business As Usual?

 
• By Urtė Fultinavičiūtė

After half a year of silence, the US FDA has published 48 product-specific guidances for generic development. With critical staff laid off, will the health agency stick to its updated PSG publishing schedule?